Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
Regeneron Japan said on December 11 that it has filed for an additional indication for its PD-1 inhibitor Libtayo (cemiplimab) for the treatment of cutaneous squamous cell carcinoma (CSCC). The application is based on data from the global pivotal PIII…
To read the full story
Related Article
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
- Gilead Files CAR-T Therapy Tecartus in Japan for MCL, B-ALL
August 21, 2026
- Tiger, Gaudi Develop Compact Cell Transport Container
August 21, 2026
- Sawai’s Solo Tenelia Copy Raises Patent Questions Ahead of December Listing
August 21, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…